A detailed history of Cumberland Partners LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cumberland Partners LTD holds 43,200 shares of VRTX stock, worth $17.2 Million. This represents 1.51% of its overall portfolio holdings.

Number of Shares
43,200
Previous 28,659 50.74%
Holding current value
$17.2 Million
Previous $13.4 Million 49.56%
% of portfolio
1.51%
Previous 1.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$460.0 - $505.78 $6.69 Million - $7.35 Million
14,541 Added 50.74%
43,200 $20.1 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $285,965 - $353,465
-728 Reduced 2.48%
28,659 $13.4 Million
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $12 Million - $13.1 Million
29,387 New
29,387 $12.3 Million
Q1 2021

May 11, 2021

SELL
$207.02 - $241.31 $23,807 - $27,750
-115 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $23,806 - $31,750
115 New
115 $27,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cumberland Partners LTD Portfolio

Follow Cumberland Partners LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cumberland Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Cumberland Partners LTD with notifications on news.